Halloween has come and gone in the US, and Americans are now gearing up for Thanksgiving and Christmas. But before the holiday season could get underway, the country went through a major political event with far-reaching implications: the midterm elections.As…
The US FDA has approved Shionogi’s novel antibiotic cefiderocol, which now carries the brand name of Fetroja, for the treatment of complicated urinary tract infections (cUTI) in patients aged 18 and older who have limited or no alternative options. The…
To read the full story
Related Article
- Cefiderocol Demonstrated Non-Inferiority to Meropenem in Global PIII: Shionogi
October 15, 2020
- Fetroja Gets FDA’s Priority Review for Nosocomial Pneumonia
June 3, 2020
- Shionogi’s Novel Antibiotic Cefiderocol Approved in Europe
April 30, 2020
- Shionogi’s Fetcroja Bags EU Panel Nod
March 4, 2020
- Shionogi’s Antibiotic Fetroja Now Available in US
February 26, 2020
- US FDA Panel Backs Shionogi’s Novel Antibiotic
October 18, 2019
- Novel Antibiotic Cefiderocol Meets Primary Endpoint in Global PIII: Shionogi
October 4, 2019
- Novel Antibiotic Cefiderocol Accepted for EMA Review: Shionogi
April 2, 2019
BUSINESS
- Tanabe to Wind Down NeuroDerm, Scrap EU Launch of Parkinson’s Drug
November 19, 2026
- Shionogi Narrows R&D Pipeline to 21 Priority Programs Across 3 Disease Areas
November 19, 2026
- Toho, SDF Hospital Conduct Emergency Drug Supply Drill
November 19, 2026
- Japan Clears Fujirebio’s Blood-Based Aβ42 Test for Alzheimer’s
November 19, 2026
- Sobi Japan to Take Over Orfadin from Astellas in December
November 19, 2026





